Zacks Investment Research upgraded shares of OncoCyte (NYSEAMERICAN:OCX) from a hold rating to a buy rating in a research report released on Saturday. Zacks Investment Research currently has $4.75 target price on the biotechnology company’s stock.

According to Zacks, “OncoCyte Corporation is primarily focused on the development of novel, non-invasive blood and urine diagnostic tests for detection of cancer. OncoCyte Corporation is based in Alameda, California. “

Separately, ValuEngine downgraded OncoCyte from a hold rating to a sell rating in a research note on Thursday, October 5th.

OncoCyte (NYSEAMERICAN:OCX) opened at $4.30 on Friday. OncoCyte has a one year low of $3.60 and a one year high of $7.85. The firm has a market capitalization of $135.14 and a P/E ratio of -6.94.

OncoCyte (NYSEAMERICAN:OCX) last released its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.01.

An institutional investor recently raised its position in OncoCyte stock. Broadwood Capital Inc. raised its stake in shares of OncoCyte Co. (NYSEAMERICAN:OCX) by 17.7% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 3,596,680 shares of the biotechnology company’s stock after buying an additional 540,000 shares during the quarter. OncoCyte comprises about 4.5% of Broadwood Capital Inc.’s investment portfolio, making the stock its 5th biggest position. Broadwood Capital Inc. owned about 11.48% of OncoCyte worth $27,155,000 as of its most recent filing with the SEC.

TRADEMARK VIOLATION NOTICE: “Zacks Investment Research Upgrades OncoCyte (OCX) to Buy” was published by Watch List News and is the property of of Watch List News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.watchlistnews.com/zacks-investment-research-upgrades-oncocyte-ocx-to-buy/1808851.html.

OncoCyte Company Profile

OncoCyte Corporation is a development-stage biotechnology company focused in the field of regenerative medicine. The Company is developing molecular cancer diagnostics utilizing a discovery platform that focuses on identifying genetic markers expressed in various types of cancer. It operates through the research and development of diagnostic tests for the detection of cancer segment.

Get a free copy of the Zacks research report on OncoCyte (OCX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.